Companies › Suzhou Suncadia Biopharmaceuticals
36 active drug programs in 201 registered trials: 118 Phase 2, 53 Phase 1, 30 Phase 3; Oncology, Immunology, Other, Respiratory; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Adebrelimab (SHR-1316) Programmed cell death 1 ligand 1 inhibitor | CD274 | Phase 3 | Locally Advanced or Metastatic Urothelial Carcinoma; PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer; Advanced Biliary Tract Cancer; Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma … | Dec 2026 |
| SHR-A1811 for Injection HER2-targeted antibody-drug conjugate | ERBB2 | Phase 3 | Advanced Colorectal Cancer; PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer; Ovarian Cancer; Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma … | Dec 2026 |
| SHR-A2009 Immunoconjugate | – | Phase 3 | Non-small Cell Lung Cancer; Advanced Solid Tumors | Dec 2026 |
| SHR-8068 Injection TSLP receptor antagonist | TSLP | Phase 3 | Advanced Biliary Tract Cancer; Advanced Hepatocellular Carcinoma; Advanced or Metastatic Non-small Cell Lung Cancer; Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma … | Dec 2026 |
| SHR-A1921 | – | Phase 3 | Ovarian Cancer; Advanced Salivary Gland Carcinoma; Advanced Breast Cancer | Dec 2026 |
| Vunakizumab (SHR-1314) Interleukin 17A inhibitor | IL17A | Phase 3 | Psoriatic Arthritis; Active Non-radiographic Axial Spondyloarthritis; Lupus Erythematosus, Systemic | Jan 2027 |
| SHR-A1912 CD47 antagonist/signal regulatory protein alpha (SIRPα) blockade | CD47 | Phase 3 | Diffuse Large B-cell Lymphoma | Mar 2027 |
| SHR-A2102 for Injection Forkhead box protein O1 (FOXO1) inhibitor | FOXO1 | Phase 3 | Recurrent Cervical Cancer; Locally Advanced or Metastatic Urothelial Carcinoma; Muscular Invasive Bladder Cancer (MIBC); Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Mar 2027 |
| SHR-1501 for Injection | – | Phase 3 | Papillary-Only Non-muscle-invasive Bladder Cancer; NMIBC | Dec 2029 |
| Trastuzumab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Triple Negative Breast Cancer | Dec 2030 |
| SHR-1701 Immunotherapy (mechanism unclear from registry) | – | Phase 3 | Gastric or Gastroesophageal Junction Cancer | – |
| SHR-1826 PD-L1 inhibitor | – | Phase 2 | NSCLC; Non-Small Cell Lung Cancer; Advanced Solid Tumors; Non-small Cell Lung Cancer (NSCLC) | Dec 2026 |
| SHR-4849 | – | Phase 2 | Malignant Solid Tumors; Advanced Solid Tumors | Dec 2026 |
| SHR-9839(sc) for injection | – | Phase 2 | Advanced Esophageal Squamous Cell Carcinoma; Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma; Solid Tumor; Advanced Solid Tumors … | Mar 2027 |
| SHR-2017 | – | Phase 2 | For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors | May 2027 |
| SHR-A1904 for Injection | – | Phase 2 | Gastric Cancer; Biliary Tract Cancer | May 2027 |
| Bevacizumab (BP102) Vascular endothelial growth factor A inhibitor | VEGFA | Phase 2 | Malignant Solid Tumors | Dec 2028 |
| SHR-1681 | – | Phase 1 | Malignant Solid Tumors | Nov 2026 |
| SHR-1894 Injection | – | Phase 1 | Dermatitis | Dec 2026 |
| SHR-6914 | – | Phase 1 | Prostate Cancer | Dec 2026 |
| SHR-7782 Injection | – | Phase 1 | Advanced Malignancy | Dec 2026 |
| SHR-3821 injection | – | Phase 1 | Advanced Solid Tumors | Jan 2027 |
| Adebelimab Anti-TIGIT antibody | TIGIT | Phase 1 | Recurrent or Metastatic Cervical Cancer | Jan 2027 |
| SHR-4375 | – | Phase 1 | Advanced Solid Tumor; Solid Tumors | Jan 2027 |
| SHR-3792 Injection | – | Phase 1 | Advanced Solid Tumors | Feb 2027 |
| SHR-4506 Injection | – | Phase 1 | Malignant Tumors of Adults | Feb 2027 |
| SHR-4642 | – | Phase 1 | Advanced Solid Tumors | Jul 2027 |
| SHR-9539 | – | Phase 1 | Multiple Myeloma | Jul 2027 |
| SHR-2524 | – | Phase 1 | Advanced Unresectable Hepatocellular Carcinoma | Oct 2027 |
| SHR-3079 | – | Phase 1 | B-cell Non-Hodgkin Lymphoma | Dec 2027 |
| SHR-3276 | – | Phase 1 | Advanced Solid Tumors | Dec 2027 |
| SHR-5421 for Injection | – | Phase 1 | Multiple Myeloma | Apr 2028 |
| SHR-4685 | – | Phase 1 | Solid Tumor | Oct 2028 |
| SHR-4298 Injection | – | Phase 1 | Malignant Solid Tumors | Nov 2028 |
| SHR-4595 for Injection | – | Phase 1 | Solid Tumor | Dec 2029 |
| SHR-4610 | – | Phase 1 | Advanced Renal Cell Carcinoma | Dec 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04950322 | SHR-1701 | Phase 3 | Gastric or Gastroesophageal Junction Cancer | Gastroenterology | May 2024 |
| NCT06282445 | Adebrelimab (SHR-1316) | Phase 2 | Colorectal Cancer Metastatic | Oncology | Mar 2025 |
| NCT06765616 | Adebrelimab (SHR-1316) | Phase 2 | Rectal Cancer | Oncology | Jul 2025 |
| NCT06277791 | Adebrelimab (SHR-1316) | Phase 2 | Clinical IVb Stage Oral Squamous Cell Carcinomas Patients | Oncology | Jul 2025 |
| NCT07055841 | Adebrelimab (SHR-1316) | Phase 2 | Squamous Cell Carcinoma of Head and Neck | Oncology | Aug 2025 |
| NCT06247956 | Adebrelimab (SHR-1316) | Phase 2 | Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma | Oncology | Dec 2025 |
| NCT06247956 | SHR-8068 Injection | Phase 2 | Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma | Oncology | Dec 2025 |
| NCT06300424 | Adebrelimab (SHR-1316) | Phase 2 | Non Small Cell Lung Cancer | Oncology | Jan 2026 |
| NCT06199973 | SHR-A1811 for Injection | Phase 3 | Advanced Colorectal Cancer | Oncology | Apr 2026 |
| NCT07542002 | Adebrelimab (SHR-1316) | Phase 2 | Pancreatic Cancer | Oncology | May 2026 |
| NCT05970666 | Adebrelimab (SHR-1316) | Phase 2 | Adebrelimab | Oncology | Nov 2026 |
| NCT06454448 | Adebrelimab (SHR-1316) | Phase 1 | Adebrelimab (SHR-1316) | Oncology | Nov 2026 |
| NCT06737731 | SHR-1681 | Phase 1 | Malignant Solid Tumors | Oncology | Nov 2026 |
| NCT06881290 | Vunakizumab (SHR-1314) | Phase 1 | Lupus Erythematosus, Systemic | Immunology | Nov 2026 |
| NCT06885814 | Adebrelimab (SHR-1316) | Phase 2 | Esophageal Squamous Cell Carcinoma | Oncology | Nov 2026 |
| NCT06149130 | Adebrelimab (SHR-1316) | Phase 2 | Breast Cancer | Oncology | Nov 2026 |
| NCT07770113 | Adebrelimab (SHR-1316) | Phase 2 | GC/GEJC | Other | Nov 2026 |
| NCT07437898 | Adebrelimab (SHR-1316) | Phase 2 | Esophageal Squamous Cell Carcinoma | Oncology | Dec 2026 |
| NCT06483282 | Adebrelimab (SHR-1316) | Phase 2 | Small Cell Lung Cancer Limited Stage | Oncology | Dec 2026 |
| NCT07123129 | SHR-7782 Injection | Phase 1 | Advanced Malignancy | Oncology | Dec 2026 |
| NCT06844474 | Adebrelimab (SHR-1316) | Phase 2 | NSCLC | Oncology | Dec 2026 |
| NCT06749730 | Adebrelimab (SHR-1316) | Phase 2 | Unresectable Biliary Tract Carcinoma | Oncology | Dec 2026 |
| NCT06454578 | Adebrelimab (SHR-1316) | Phase 2 | Carcinoma, Hepatocellular | Oncology | Dec 2026 |
| NCT06610734 | Adebrelimab (SHR-1316) | Phase 2 | Small Cell Lung Cancer Extensive Stage | Oncology | Dec 2026 |
| NCT06840002 | SHR-A1811 for Injection | Phase 1 | Ovarian Cancer | Oncology | Dec 2026 |
| NCT06844474 | SHR-1826 | Phase 2 | NSCLC | Oncology | Dec 2026 |
| NCT06844474 | SHR-1826 | Phase 2 | NSCLC | Oncology | Dec 2026 |
| NCT06671379 | SHR-A2009 | Phase 3 | Non-small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT07414602 | SHR-1894 Injection | Phase 1 | Dermatitis | Immunology | Dec 2026 |
| NCT06443489 | SHR-4849 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2026 |
| NCT07735377 | SHR-6914 | Phase 1 | Prostate Cancer | Oncology | Dec 2026 |
| NCT06465563 | Adebrelimab (SHR-1316) | Phase 2 | Biliary Tract Cancer | Oncology | Dec 2026 |
| NCT06485544 | Adebrelimab (SHR-1316) | Phase 2 | Small Cell Lung Cancer (SCLC) | Oncology | Dec 2026 |
| NCT07141264 | Adebrelimab (SHR-1316) | Phase 2 | SCLC,Extensive Stage | Oncology | Dec 2026 |
| NCT06741020 | Adebrelimab (SHR-1316) | Phase 1 | Hepatocellular Carcinoma (HCC) | Oncology | Dec 2026 |
| NCT06465563 | SHR-8068 Injection | Phase 2 | Biliary Tract Cancer | Oncology | Dec 2026 |
| NCT05924256 | SHR-A1921 | Phase 2 | Advanced Salivary Gland Carcinoma | Oncology | Dec 2026 |
| NCT05114759 | SHR-A2009 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2026 |
| NCT06620848 | Adebrelimab (SHR-1316) | Phase 2 | Biliary Tract Cancer | Oncology | Dec 2026 |
| NCT05076682 | Adebrelimab (SHR-1316) | Phase 2 | Triple-negative Breast Cancer | Oncology | Dec 2026 |
| NCT06700421 | Adebrelimab (SHR-1316) | Phase 2 | Unresectable Locally Advanced Non-small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06418594 | Adebrelimab (SHR-1316) | Phase 2 | HER2-negative Breast Cancer Brain Metastases | Oncology | Dec 2026 |
| NCT06500208 | Adebrelimab (SHR-1316) | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT06776770 | Adebrelimab (SHR-1316) | Phase 1 | Gastric Cancer | Oncology | Dec 2026 |
| NCT06394492 | SHR-A1921 | Phase 3 | Ovarian Cancer | Oncology | Dec 2026 |
| NCT06091124 | Adebrelimab (SHR-1316) | Phase 2 | Neuroendocrine Carcinoma of the Bladder | Oncology | Jan 2027 |
| NCT06618651 | SHR-3821 injection | Phase 1 | Advanced Solid Tumors | Oncology | Jan 2027 |
| NCT06208462 | Adebrelimab (SHR-1316) | Phase 2 | Intrahepatic Cholangiocarcinoma | Oncology | Jan 2027 |
| NCT06859775 | SHR-A1811 for Injection | Phase 1 | Recurrent or Metastatic Cervical Cancer | Oncology | Jan 2027 |
| NCT06859775 | SHR-8068 Injection | Phase 1 | Recurrent or Metastatic Cervical Cancer | Oncology | Jan 2027 |
| NCT07298772 | SHR-4375 | Phase 1 | Advanced Solid Tumor | Oncology | Jan 2027 |
| NCT06859775 | Adebelimab | Phase 1 | Recurrent or Metastatic Cervical Cancer | Oncology | Jan 2027 |
| NCT06640257 | Vunakizumab (SHR-1314) | Phase 3 | Psoriatic Arthritis | Immunology | Jan 2027 |
| NCT06907628 | SHR-3792 Injection | Phase 1 | Advanced Solid Tumors | Oncology | Feb 2027 |
| NCT07068932 | SHR-4506 Injection | Phase 1 | Malignant Tumors of Adults | Oncology | Feb 2027 |
| NCT07452601 | Adebrelimab (SHR-1316) | Phase 2 | Esophageal Squamous Cell Carcinoma | Oncology | Feb 2027 |
| NCT06298968 | Adebrelimab (SHR-1316) | Phase 2 | Intrahepatic Cholangiocarcinoma | Oncology | Feb 2027 |
| NCT06467617 | Adebrelimab (SHR-1316) | Phase 2 | Non Small Cell Lung Cancer | Oncology | Mar 2027 |
| NCT06296563 | Adebrelimab (SHR-1316) | Phase 2 | Intrahepatic Cholangiocarcinoma | Oncology | Mar 2027 |
| NCT07059221 | Adebrelimab (SHR-1316) | Phase 1 | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Oncology | Mar 2027 |
The 60 nearest readouts of 201 trials; the rest in the app.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.